The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05034952
Recruitment Status : Completed
First Posted : September 5, 2021
Last Update Posted : December 7, 2022
Sponsor:
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty.

Condition or disease Intervention/treatment Phase
Acute Pain Drug: VX-548 Drug: HB/APAP Drug: Placebo (matched to VX-548) Drug: Placebo (matched to HB/APAP) Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 303 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-dose Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
Actual Study Start Date : August 30, 2021
Actual Primary Completion Date : December 5, 2021
Actual Study Completion Date : December 21, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: VX-548
Participants will be randomized to receive different dose levels of VX-548.
 Drug: VX-548
Tablets for oral administration.

Drug: Placebo (matched to HB/APAP)
Placebo matched to HB/APAP for oral administration.
Active Comparator: Hydrocodone bitartrate/ acetaminophen (HB/APAP)
Participants will receive HB/APAP.
 Drug: HB/APAP
Capsules for oral administration.

Drug: Placebo (matched to VX-548)
Placebo matched to VX-548 for oral administration.
Placebo Comparator: Placebo
Participants will receive placebos matched to VX-548 and HB/APAP.
 Drug: Placebo (matched to VX-548)
Placebo matched to VX-548 for oral administration.

Drug: Placebo (matched to HB/APAP)
Placebo matched to HB/APAP for oral administration.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time-weighted sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) at Rest 0 to 48 Hours (SPIDr0-48) After the First Dose of Study Drug [ Time Frame: 0 to 48 Hours After the First Dose of Study Drug ]

Secondary Outcome Measures :
  1. Time-weighted SPID as Recorded on an NPRS at Rest 0 to 24 Hours (SPIDr0-24) After the First Dose of Study Drug [ Time Frame: 0 to 24 Hours After the First Dose of Study Drug ]
  2. Proportions of Participants With >=30 Percent (%), >=50%, and >=70% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug [ Time Frame: At 48 Hours After the First Dose of Study Drug ]
  3. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 up to Day 17 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Before Surgery:

    • Participant scheduled to undergo an abdominoplasty without collateral procedures

  • After Surgery:

    • Participant is lucid and able to follow commands
    • All analgesic guidelines were followed during and after the abdominoplasty
    • Abdominoplasty procedure duration <=3 hours without collateral procedures (for example., liposuction)

Key Exclusion Criteria

  • Before Surgery:

    • Prior history of abdominoplasty, intra-abdominal and/or pelvic surgery
    • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
    • Any prior surgery within 1 month before the first study drug

  • After Surgery:

    • Participant had medical complications during the abdominoplasty that, in the opinion of the investigator, should preclude randomization
    • Participant had collateral procedures during the abdominoplasty

Other protocol defined inclusion/exclusion criteria may apply

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05034952


Locations
Layout table for location information
United States, Arizona
Arizona Research Center
Phoenix, Arizona, United States, 85053
United States, California
Lotus Clinical Research
Pasadena, California, United States, 91105
United States, Maryland
Chesapeake Research Group
Pasadena, Maryland, United States, 21122
United States, Ohio
Midwest Clinical Research Center
Dayton, Ohio, United States, 45417
United States, Texas
First Surgical Hospital
Bellaire, Texas, United States, 77401
Endeavor Clinical Trials
San Antonio, Texas, United States, 78229
United States, Utah
JBR Clinical Research
Salt Lake City, Utah, United States, 84107
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT05034952    
Other Study ID Numbers: VX21-548-102
First Posted: September 5, 2021    Key Record Dates
Last Update Posted: December 7, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Pain
Pain
Neurologic Manifestations
Acetaminophen
Analgesics, Non-Narcotic
 Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics